Search clinical trials for: Ongentys

Total 8 results

Bial - Portela C S.A.

Completed

Bioavailability and Bioequivalence Between Two Active Pharmaceutical Ingredient (API) Sources of Opicapone (OPC)

Parkinson Disease

United Kingdom
Neurocrine Biosciences

Completed

Opicapone Treatment Initiation Open-Label Study (OPTI-ON)

Parkinson Disease

United States
Bial - Portela C S.A.

Completed

Relative Bioavailability and Bioequivalence of Opicapone

Parkinson Disease

United Kingdom
Bial - Portela C S.A.

Completed

Bioavailability and Bioequivalence Study of Two Different Sources of Opicapone

Parkinson Disease

Germany
Bial - Portela C S.A.

Completed

Effect of Food on Opicapone

Parkinson Disease
Bial - Portela C S.A.

Completed

Safety and Effectiveness of Opicapone Plus Standard of Care in Elderly Patients With Parkinson's Disease

Parkinson Disease

United Kingdom
SK Chemicals Co., Ltd.

Completed

A Study to Evaluate the add-on Efficacy and Safety of Opicapone 50 mg or an Extra Dose of L-DOPA 100 mg for the Treatment of Wearing-off in Patients With PD

Parkinson Disease

Korea, Republic of
Bial - Portela C S.A.

Completed

Efficacy and Safety of Opicapone in Clinical Practice (OPTIPARK)

Parkinson's Disease With Wearing-off Motor Fluctuations

Germany

3

Subscribe